Medication info
Olmesartan Medoxomil 20/20 mg

Olmesartan Medoxomil 20/20 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
White or yellowish round film-coated tablets
Packaging
30 tablets/box [30 tablets (10 tablets/Alu-Alu) × 3]
Approval status
Active

MFDS item code 202003956 · Approved 2020.05.28

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that this medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose while their condition is closely monitored. 2. Elderly patients No dose adjustment is necessary when administering this medicine to elderly patients aged 65 years or older. Although no overall differences in the efficacy and safety of this medicine have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and the dose may be increased to a maximum of 20mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20mg once daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5mg. Administration of the 40mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of the 40mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
The safety and efficacy in children under 18 years of age have not been established.

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
  • family history of early coronary heart disease.
View approved original text

This medication is prescribed for patients who require the combined use of two ingredients, olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil helps treat essential hypertension. Rosuvastatin is used to manage various forms of hypercholesterolemia and hyperlipidemia that are difficult to control with diet and exercise, particularly playing a role in slowing the progression of atherosclerosis. Additionally, it contributes to reducing the risk of stroke, myocardial infarction, and vascular revascularization in patients with high cardiovascular risk. This medication treats both hypertension and dyslipidemia to improve cardiovascular health.

How to take

Adult dose

This medicine is administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that this medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose while their condition is closely monitored. 2. Elderly patients No dose adjustment is necessary when administering this medicine to elderly patients aged 65 years or older. Although no overall differences in the efficacy and safety of this medicine have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and the dose may be increased to a maximum of 20mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10mg once daily, which is adequate for most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20mg once daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5mg. Administration of the 40mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of the 40mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

The safety and efficacy in children under 18 years of age have not been established.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, therefore, it should be discontinued immediately upon confirmation of pregnancy. People who are allergic to this medication or its components, pregnant or potentially pregnant women, or women who are nursing should not take this medication. Patients with very poor kidney function or undergoing kidney dialysis, severe liver disease, biliary obstruction, or with muscle disorders should also avoid this medication. Patients with low blood pressure or low body sodium, unstable kidney function, or at risk for hyperkalemia should exercise special caution when taking this medication, and should regularly check their condition through blood tests. This medication can cause muscle pain or weakness, and rarely severe muscle breakdown, so any abnormalities in the muscles should be reported to healthcare professionals immediately. Furthermore, this medication may affect liver function, so regular liver function tests should be performed before and during treatment. Avoid alcohol consumption during treatment, and exercise extra caution if there is a history of liver disease. Dizziness or drowsiness may occur, so caution should be taken when driving or operating hazardous machinery. This medication may interact with other drugs, so any other medications being taken should be disclosed to a doctor or pharmacist, particularly caution is advised when used in combination with potassium-sparing diuretics, lithium, and non-steroidal anti-inflammatory drugs. Women who are pregnant or planning to become pregnant should strictly use appropriate contraception, and immediately discontinue use upon confirmation of pregnancy. If nursing, this medication should be avoided due to potential effects on the baby, or breastfeeding should be discontinued. Safety and effectiveness have not been established for patients under 18 years of age. In case of overdose, symptoms such as hypotension and palpitations may occur, so immediate contact with healthcare professionals is necessary, and liver and muscle conditions should be carefully monitored. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

ALT elevation, AST elevation, increased serum creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest pain, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, dyslipidemia, hyperuricemia, joint pain, arthritis, myalgia, rash, facial edema, asthenia, vascular edema, anaphylaxis, vomiting, chronic malabsorption-like enteropathy, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness including positional dizziness, palpitations, elevated blood pressure, low back pain, pruritus, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reaction including angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy including myositis, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, joint pain, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders including insomnia and nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained at room temperature between 1°C and 30°C. This will help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

White or yellowish round film-coated tablets

Package unit

30 tablets/box [30 tablets (10 tablets/Alu-Alu) × 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.